These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22749235)

  • 21. Hepatitis B vaccine immunogenicity in patients with chronic HCV infection at one year follow-up: the effect of interferon-alpha therapy.
    Chlabicz S; Grzeszczuk A; Łapiński TW
    Med Sci Monit; 2002 May; 8(5):CR379-83. PubMed ID: 12011781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects for prophylactic and therapeutic vaccines against hepatitis C virus.
    Feinstone SM; Hu DJ; Major ME
    Clin Infect Dis; 2012 Jul; 55 Suppl 1():S25-32. PubMed ID: 22715210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus.
    Torresi J; Johnson D; Wedemeyer H
    J Hepatol; 2011 Jun; 54(6):1273-85. PubMed ID: 21236312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?
    Missale G; Cariani E; Ferrari C
    Dig Liver Dis; 2004 Nov; 36(11):703-11. PubMed ID: 15570998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unscrambling hepatitis C virus-host interactions.
    Chisari FV
    Nature; 2005 Aug; 436(7053):930-2. PubMed ID: 16107831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Future therapies for hepatitis C.
    Pawlotsky JM; Gish RG
    Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute hepatitis C virus infection.
    Chung RT
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S14-7. PubMed ID: 16265608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus.
    Horner SM; Gale M
    J Interferon Cytokine Res; 2009 Sep; 29(9):489-98. PubMed ID: 19708811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive immune responses in acute and chronic hepatitis C virus infection.
    Bowen DG; Walker CM
    Nature; 2005 Aug; 436(7053):946-52. PubMed ID: 16107834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1.
    Zekri AR; Moharram RA; Mohamed WS; Bahnassy AA; Alam El-Din HM; Abo-Shadi MM; Zayed NA; El-Magzangy H; Abdel-Aziz AO; Esmat G
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):450-6. PubMed ID: 19858727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus-mediated modulation of cellular immunity.
    Brenndörfer ED; Sällberg M
    Arch Immunol Ther Exp (Warsz); 2012 Oct; 60(5):315-29. PubMed ID: 22911132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of selected HLA tissue compatibility antigens on the course and efficacy of viral hepatitis C treatment--actual knowledge position.
    Łoś-Rycharska E; Szaflarska-Popławska A
    Adv Med Sci; 2009; 54(1):14-9. PubMed ID: 19482730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunology of hepatitis B and hepatitis C virus infections.
    Boonstra A; Woltman AM; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1049-61. PubMed ID: 19187866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.
    Thimme R; Binder M; Bartenschlager R
    FEMS Microbiol Rev; 2012 May; 36(3):663-83. PubMed ID: 22142141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice.
    Chen J; Zhao Y; Zhang C; Chen H; Feng J; Chi X; Pan Y; Du J; Guo M; Cao H; Chen H; Wang Z; Pei R; Wang Q; Pan L; Niu J; Chen X; Tang H
    Cell Res; 2014 Sep; 24(9):1050-66. PubMed ID: 25155355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CC-chemokine receptor 5 (CCR5) in hepatitis C--at the crossroads of the antiviral immune response?
    Ahlenstiel G; Woitas RP; Rockstroh J; Spengler U
    J Antimicrob Chemother; 2004 Jun; 53(6):895-8. PubMed ID: 15128728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Change of HCV-RNA levels in liver tissue and interferon responsiveness in patients with chronic hepatitis C].
    Takeuchi M; Kaneko S; Unoura M; Kobayashi K
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):969-74. PubMed ID: 7563912
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.